Eli Lilly and Company
LLY
$757.20
$5.750.77%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.38% | 32.00% | 27.41% | 31.87% | 29.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.38% | 32.00% | 27.41% | 31.87% | 29.76% |
| Cost of Revenue | 25.81% | 18.87% | 14.03% | 14.18% | 15.27% |
| Gross Profit | 38.99% | 35.44% | 31.04% | 36.93% | 33.92% |
| SG&A Expenses | 21.20% | 17.16% | 14.23% | 12.61% | 14.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.50% | 18.02% | 16.59% | 17.99% | 20.70% |
| Operating Income | 70.85% | 62.24% | 51.98% | 67.36% | 53.25% |
| Income Before Tax | 79.88% | 93.46% | 65.26% | 23.47% | 20.35% |
| Income Tax Expenses | 75.31% | 59.06% | 54.32% | 110.36% | 138.81% |
| Earnings from Continuing Operations | 80.93% | 102.08% | 67.79% | 13.00% | 7.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.93% | 102.08% | 67.79% | 13.00% | 7.94% |
| EBIT | 70.85% | 62.24% | 51.98% | 67.36% | 53.25% |
| EBITDA | 64.53% | 56.47% | 46.40% | 58.75% | 46.10% |
| EPS Basic | 81.01% | 102.08% | 67.85% | 12.99% | 8.00% |
| Normalized Basic EPS | 70.28% | 61.48% | 51.33% | 68.55% | 55.05% |
| EPS Diluted | 81.17% | 102.11% | 67.65% | 12.86% | 7.86% |
| Normalized Diluted EPS | 70.12% | 61.24% | 51.05% | 68.64% | 55.16% |
| Average Basic Shares Outstanding | -0.01% | 0.04% | 0.04% | -0.02% | -0.07% |
| Average Diluted Shares Outstanding | 0.07% | 0.18% | 0.18% | -0.08% | -0.12% |
| Dividend Per Share | 15.14% | 15.04% | 15.10% | 15.17% | 15.23% |
| Payout Ratio | -0.36% | -0.43% | -0.31% | 0.02% | 0.07% |